Medical Condition News

RSS

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Silencing two microRNAs may help treat age-related macular degeneration

Blocking two tiny molecules of RNA - a chemical cousin of DNA - appears to suppress the abnormal growth of blood vessels that occurs in degenerative eye disorders, UT Southwestern Medical Center researchers have found.

7 Jun 2011

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Oxford BioMedicaplc, a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc., a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the Company's proprietary 5T4 tumour antigen.

7 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Tai Chi may help overcome cognitive decline in patients receiving chemotherapy

According to the American Cancer Society, more than 11.4 million Americans are currently living with cancer. While cancer treatments are plentiful, many have negative side effects. Previous studies have indicated that a significant number of patients who receive chemotherapy also experience cognitive declines, including decreases in verbal fluency and memory.

7 Jun 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).

7 Jun 2011

Researchers reveal surprising link between cell's skeleton and organ size

A group of scientists at the Instituto Gulbenkian de Ci-ncia, in Portugal, have uncovered a surprising link between the cell's skeleton and organ size. The team, led by Florence Janody, show in the journal Development, that one of the proteins that regulates the skeleton of the cell also acts to blocks activation of genes that promote cell survival and proliferation.

7 Jun 2011

Homelessness and mental illness link explored in RMIT study

In a new study by the RMIT University, Victoria researchers looked at cases of 4,291 people using homelessness services in the city. Dr Guy Johnson and Professor Chris Chamberlain found almost half of them - 46 per cent - lost their homes after a family breakdown. This is contrary to the long held belief that most homeless people are mentally unstable.

7 Jun 2011

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2011

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Celator Pharmaceuticals today announced positive clinical results in elderly patients with newly-diagnosed secondary acute myeloid leukemia (sAML) treated with CPX-351 Liposome Injection.

7 Jun 2011

3M introduces Kind Removal Silicone Tape for patients with sensitive, at-risk skin

3M Skin and Wound Care introduces 3M Kind Removal Silicone Tape with a new, silicone-based, adhesive technology that provides an optimal balance of securement and gentleness.

7 Jun 2011

Frog skin proteins could treat cancer, diabetes and stroke: New discovery

Scientists at Queen's University Belfast have discovered proteins in frog skins which could be used to treat cancer, diabetes, stroke and transplant patients by regulating the growth of blood vessels.

7 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Cylene Pharmaceuticals, Inc. today announced the presentation of encouraging data from an ongoing Phase I dose-escalation trial of CX-4945 in patients with solid tumors at the 2011 American Society of Clinical Oncology (ASCO) annual meeting held on June 4-8 in Chicago, IL.

6 Jun 2011

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois.

6 Jun 2011

Senescent melanoma cells express an inflammatory secretome

Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In this paper, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile ("secretome") that can ultimately promote metastasis and contribute to melanoma relapse.

6 Jun 2011

MedPro Imaging invests in dedicated transducer repair technology

Designed to counter a growing emphasis in the industry on probe exchange programs, MedPro Imaging's Advanced Probe Repair Division today announced that it has added 4D transducer repair capabilities, featuring proprietary computer-based technology and processes for fast, consistent repairs.

6 Jun 2011

Brown fat could help treat obesity and diabetes

A new study suggests that many adults have large amounts of brown fat, the "good" fat that burns calories to keep us warm, and that it may be possible to make even more of this tissue.

6 Jun 2011

Consumption of moderately reduced carbohydrate diet can help reduce total body fat

A modest reduction in consumption of carbohydrate foods may promote loss of deep belly fat, even with little or no change in weight, a new study finds. Presentation of the study results will be Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Medical Condition News

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

Silencing two microRNAs may help treat age-related macular degeneration

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tai Chi may help overcome cognitive decline in patients receiving chemotherapy

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Researchers reveal surprising link between cell's skeleton and organ size

Homelessness and mental illness link explored in RMIT study

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

3M introduces Kind Removal Silicone Tape for patients with sensitive, at-risk skin

Frog skin proteins could treat cancer, diabetes and stroke: New discovery

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Senescent melanoma cells express an inflammatory secretome

MedPro Imaging invests in dedicated transducer repair technology

Brown fat could help treat obesity and diabetes

Consumption of moderately reduced carbohydrate diet can help reduce total body fat

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News